Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 237-240

  Zauderer, Marjorie G ^a   Drilon, Alex ^a   Kadota, Kyuichi ^b   Huberman, Kety ^b   Sima, Camelia S ^b   Bergagnini, Isabella ^a   Sumner, Dyana K ^a   Travis, William D ^b   Heguy, Adriana ^b   Ginsberg, Michelle S ^b   Holodny, Andrei I ^b   Riely, Gregory J ^a   Kris, Mark G ^a   Krug, Lee M ^a   Pietanza, M Catherine ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alkylating agent; Biomarker; Chemotherapy; MGMT; SCLC; Temozolomide

Indexed keywords

DNA METHYLTRANSFERASE; ONDANSETRON; TEMOZOLOMIDE; TUMOR MARKER; ALKYLATING AGENT; DACARBAZINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DNA METHYLATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PNEUMONIA; POLYMERASE CHAIN REACTION; PROMOTER REGION; PRURITUS; RADIATION INJURY; RADIATION NECROSIS; RASH; SENSORY NEUROPATHY; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; DRUG ADMINISTRATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84908405540     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.007     Document Type: Article

References (16)

1. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17(2):658-667.
2. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25(15):2086-2092.
3. O'Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cucevia B., Juhasz G., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24(34):5441-5447.
4. Esteller M., Herman J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23(1):1-8.
5. Toyooka S., Toyooka K.O., Maruyama R., Virmani A.K., Girard L., Miyajima K., et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001, 1(1):61-67.
6. Hammond L.A., Eckardt J.R., Baker S.D., Eckhardt S.G., Dugan M., Forral K., et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999, 17(8):2604-2613.
7. Brandes A.A., Tosoni A., Cavallo G., Bertorelle R., Gioia V., Franceschi E., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006, 95(9):1155-1160.
8. Wick A., Felsberg J., Steinbach J.P., Herrlinger U., Platten M., Blaschke B., et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007, 25(22):3357-3361.
9. Pietanza M.C., Kadota K., Huberman K., Sima C.S., Fiore J.J., Sumner D.K., et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012, 18(4):1138-1145.
10. Gilbert M., Wang M., Aldape K., Stupp R., Hegi M., Jaeckle K. A randomized phase III trial comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed glioblastoma. J Clin Oncol 2011, 29:S2006.
11. Paz M.F., Yaya-Tur R., Rojas-Marcos I., Reynes G., Pollan M., Aguirre-Cruz L., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10(15):4933-4938.
12. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343(19):1350-1354.
13. Sciuscio D., Diserens A.C., van Dommelen K., Martinet D., Jones G., Janzer R.C., et al. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res 2011, 17(2):255-266.
14. Hegi M.E., Liu L., Herman J.G., Stupp R., Wick W., Weller M., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26(25):4189-4199.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
16. Palma J.P., Wang Y.C., Rodriguez L.E., Montgomery D., Ellis P.A., Bukofzer G., et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009, 15(23):7277-7290.